Clinical trials: Refractory Symptoms
Leukemia, Lymphocytic, Chronic, B-Cell
Humanized CAR-T Therapy for Treatment of B Cell Malignancy
The present study evaluates the safety and efficacy of humanized Chimeric antigen receptor T cells (CAR-T) in treating recurrent or refractory B cell malignancy targeting CD19 with a humanized scFv.
- Trial name
- NCT02782351
- Testing
- CAR-T
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Kai Lin Xu; Jun Nian Zheng
Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB)
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Recurrent, Refractory, Neuroblastoma (NB), Neuroblastoma in Children
- Trial name
- NCT06674265
- Testing
- Allogenic NK cells infusion
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Marzieh Ebrahimi
Epilepsy
Atkins Plus KetoCal for Childhood Epilepsy
The modified Atkins diet (MAD) is a relatively new, alternative dietary therapy for intractable childhood and adult epilepsy. Recent evidence suggests that a strict, highly ketotic, first month may be advantageous to both…
- Trial name
- NCT00681239
- Testing
- Modified Atkins diet and KetoCal
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Advanced Cancer
Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated
The purpose of this study is to describe how often advanced cancer patients experience breakthrough pain (BTcP), and to describe how this pain is treated, and how effective these treatments are.
- Trial name
- Break-1 (NCT02069067)
- Where
- 3 sites in Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Multiple Myeloma
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
This is a Phase II trial evaluating the overall response rate, safety and tolerability to azacitidine in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00412919
- Testing
- Azacitidine
- Where
- Australia
- Volunteers
- 7 people
- Sponsor
- Bayside Health
Lymphoma
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Trial name
- NCT00002941
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 69 people
- Sponsor
- Children's Oncology Group
Recurrent and Refractory Solid Tumors
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with…
- Trial name
- NCT03245151
- Testing
- Lenvatinib, Everolimus
- Where
- 50 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Lymphoma, Lymphoid Hematological Malignancies
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy.
- Trial name
- NCT07472972
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Leukemia, Acute Leukemia in Relapse
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia in a dose-escalation way.
- Conditions
- Acute Leukemia, Acute Leukemia in Relapse, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemia
- Trial name
- NCT03672851
- Testing
- anti-CD123 CAR-T treatment
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
B Cell, Acute Lymphoblastic Leukemia
Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias
Background Acute lymphoblastic leukemia (ALL) accounts for about 25 percent of childhood cancers and for about 20 percent of adult leukemias.
- Conditions
- B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory
- Trial name
- NCT05969002
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Acute Myelogenous Leukemia
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs.
- Trial name
- NCT00939653
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
This clinical trial studies fludarabine phosphate and total-body radiation followed by donor peripheral blood stem cell transplant and immunosuppression in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00014235
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Epilepsy
Transcranial Magnetic Stimulation to Treat Epilepsy
This study will use transcranial magnetic stimulation, or TMS (described below), to treat epilepsy in certain patients whose seizures persist despite optimum medical treatment.
- Trial name
- NCT00048490
- Testing
- transcranial magnetic stimulation (TMS)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Neuroblastoma, Medulloblastoma
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
The purpose of this research study is to evaluate a new investigational drug (TPI 287) for neuroblastoma and medulloblastoma both alone and in combination with temozolomide (a currently approved drug).
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Trial name
- NCT00867568
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Giselle Sholler
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
This is an open label, interventional, randomized phase II trial comparing StemRegenin-1 (SR-1) cultured umbilical cord blood (experimental arm) to unmanipulated umbilical cord blood (standard of care arm) transplantation after a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia
- Trial name
- NCT02765997
- Testing
- Unmanipulated UCB, SR-1 UCB
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional…
- Conditions
- Leukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes
- Trial name
- NCT00949117
- Testing
- Ensure, PediaSure, cyproheptadine hydrochloride
- Volunteers
- 9 people
- Sponsor
- University of South Florida
Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia
CAR T Cell Therapy Related Cardiovascular Outcomes
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies.
- Conditions
- Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- CARTCO (NCT05130489)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College London Hospitals
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT04678336
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Henoch-Schönlein Purpura, Gastrointestinal Injury
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
Henoch Schönlein purpura (HSP) is the most common type of vasculitis in children, with an incidence of ~10/100,000, whereas >90% of the patients develop symptoms at <10 years of age.
- Conditions
- Henoch-Schönlein Purpura, Gastrointestinal Injury, Mycophenolate Mofetil
- Trial name
- NCT05951517
- Testing
- MMF
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University